ArticleJournal of biological engineering2025
Simultaneous multigene integration in Aspergillus fumigatus using CRISPR/Cas9 and endogenous counter-selectable markers.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- CRISPR-Cas9 Gene Editing inBiology · 2025Review
- Research Progress in Mutagenesis Techniques forMini reviews in medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe discovery of CRISPR/Cas9 and its subsequent accessibility in daily research initiated a new era in genome editing. This game-changing genetic instrument enabled a vast array of challenging applications requiring site-specific genome engineering as well as applications involving the equipment of cells with additional genetic traits. Despite the undisputed benefits of this technology, for facile and efficient selection of successfully manipulated cells selectable markers remain indispensable. Over the past years endogenous counter-selectable markers have come into focus in antifungal research enabling site-directed integration of multiple genes into the genome of the human mold pathogen Aspergillus fumigatus. However, gene cassettes had to be transformed in a consecutive manner keeping multigene integrations laborious and time-consuming.
resultsIn this work, we coupled the use of CRISPR/Cas9 with endogenous counter-selectable markers to achieve the simultaneous integration of multiple expression cassettes. The three markers used in this work included the herein employed azgA and the previously identified fcyB and cntA, responsible for 8-azaguanine, 5-fluorocytosine and 5-fluorouridine uptake, respectively. Exploiting their role in uptake of different selective agents, a triple selective transformation procedure and genomic integration of three expression cassettes in A. fumigatus was successfully accomplished. In addition to three distinct cellular reporters, we introduced strain-specific fluorescent reporters into four isolates displaying different levels of antifungal azole resistance to subsequently visualize and monitor their growth patterns in the same growth environment.
conclusionsThe technology described in this study significantly streamlines the genetic manipulation process, reducing both time and labor associated with sequential transformations. By enabling the introduction of multiple genetic traits in a single transformation event, this strategy provides a flexible and efficient platform for a wide range of applications. As such, it enhances the potential for rapid and effective multigene integration, advancing the field of genetic engineering in fungi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.